Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Update

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 66,700 shares, a growth of 46.6% from the February 13th total of 45,500 shares. Based on an average daily volume of 6,080,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.6% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.

Phio Pharmaceuticals Trading Down 3.0 %

Shares of Phio Pharmaceuticals stock traded down $0.04 during trading hours on Friday, reaching $1.29. 144,238 shares of the company’s stock were exchanged, compared to its average volume of 7,689,282. Phio Pharmaceuticals has a 52-week low of $1.22 and a 52-week high of $9.99. The company has a fifty day moving average of $1.98 and a 200-day moving average of $2.52. The firm has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.12 and a beta of 1.28.

Institutional Trading of Phio Pharmaceuticals

A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC bought a new stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned 0.59% of Phio Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 57.31% of the stock is owned by institutional investors.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.